ClinicalTrials.govpublic full text
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
endometrial cancer, endometrial adenocarcinoma, immune checkpoint inhibitors (icis), anti-pd-1/ctla4 bi-specific antibody, antiangiogenic agents, chemotherapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 880806
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.